SRT2104

In preclinical studies, SRT2104 demonstrated a lowering of fasting blood glucose and insulin, reduced weight gain, increased energy expenditure, improved exercise tolerance and improved insulin sensitivity in the diet-induced obesity model of Type 2 Diabetes. (See Publications and Meetings)

SRT2104 was Sirtris' first NCE to enter human trials. The Phase I program in healthy volunteers demonstrated favorable safety and tolerability. (see Scientific Publications). The Phase I program was followed by a small translational medicine study in acute inflammation as well as two clinical studies in Type 2 Diabetes. SRT2104 continues development in separate Phase II trials in psoriasis, ulcerative colitis and vascular disorders.

SRT2379

Our second NCE to enter human clinic trials is SRT2379, which is chemically and structurally distinct from resveratrol and SRT2104. In preclinical studies, SRT2379 demonstrated efficacy in multiple disease models of diabetes and inflammation. SRT2379 has completed Phase I clinical assessment for safety, tolerability and pharmacokinetics. In addition, SRT2379 has completed a small translational medicine study of acute inflammation in normal human volunteers.

SRT3025

Our third NCE, which has been shown to have broad pharmacological activity in animal models of metabolic, inflammatory and neurodegenerative disease (See Publications and Meetings). SRT2379 has completed Phase I clinical assessment for safety, tolerability and pharmacokinetics.